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Abstract
Background: The human FHIT gene is inactivated early in the development of many human
cancers and loss of Fhit in mouse predisposes to cancer while reintroduction of FHIT suppresses
tumor formation via induction of apoptosis. Fhit protein, a diadenosine polyphosphate hydrolase,
does not require hydrolase activity to function in tumor suppression and may signal for apoptosis
as an enzyme-substrate complex. Thus, high affinity nonhydrolyzable substrate analogs may either
promote or antagonize Fhit function, depending on their features, in Fhit + cells. Previously
synthesized analogs with phosphorothioadenosyl substitutions and "supercharged" branches do not
bind better than natural substrates and thus have limited potential as cellular probes.
Results: Here we link adenosine 5'-O-phosphates and phosphorothioates to short-chain polyols
to generate a series of substrate analogs. We obtain structure-activity data in the form of in vitro
Fhit inhibition for four types of analog substitutions and describe two compounds, inhibitory
constants for which are 65 and 75-fold lower than natural substrates.
Conclusions:  The best Fhit inhibitors obtained to date separate two or more 5'-O-
phosphoromonothioadenosyl moieties with as many bond lengths as in AppppA, maintain oxygen
at the location of the α -β  bridging oxygen, and replace carbon for the β  phosphorus.
Background 
Loss of Fhit protein is among the earliest known events
in the development of a variety of the most common and
lethal human malignancies [1]. Loss of Fhit leads to cells
that are deficient in programmed cell death and that
form tumors in mice while Fhit reexpression in Fhit-can-
cer cells reduces tumorigenicity and restores pro-
grammed cell death [2–6]. Infection of Fhit +/- mice
with viruses that re-express Fhit reduce cancer occur-
rence [7], apparently by killing pre-neoplastic cells that
have lost the wild-type Fhit allele. Human Fhit protein, a
member of the Fhit branch of the histidine triad super-
family of nucleotide-binding proteins, binds and hydro-
lyzes diadenosine polyphosphates such as ApppA and
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AppppA (1) into AMP plus ADP and ATP, respectively
[8–10]. His96, which is responsible for covalent catalysis
and more than 4×  106-fold of rate enhancement in App-
pA hydrolysis [9,11–13], is nonetheless dispensable for
ApppA-binding and tumor suppression, suggesting that
Fhit function in tumor suppression depends on forma-
tion of an E-S complex [2,12]. If Fhit-substrate complex-
es promote tumor suppression by stimulating a pro-
apoptotic effector, then Fhit inhibitors that resemble
natural substrates may promote Fhit function. Similarly,
Fhit inhibitors with normative features may antagonize
Fhit function. Either class of compounds may be impor-
tant in dissecting Fhit cell biology and regulating apopto-
sis.
Making use of a synthesis strategy to link adenosine 5'-O-
phosphates and phosphorothioates to short-chain poly-
ols [14], we evaluate four inhibitor parameters and ob-
tain compounds, inhibitory constants for which are as
much as 70-fold lower than natural substrates. Key fea-
tures of the best candidate agonist compound 6b and
candidate antagonist compound 12b are conservation of
the length of the polyphosphate replacement, use of 5'-
O-phosphorothioadenosyl residues, no replacement for
oxygen at the location of the α -β  bridging oxygen, and re-
placement of carbon for the β  phosphorus. Compound
12b contains additional negatively charged substituents
that may facilitate Fhit inhibition [15] while rendering
the compound antagonistic to Fhit function in the cell.
Covalent structures of AppppA (1) and compounds 6b
and 12b are provided in Figure 1.
Results and Discussion 
A series of compounds 2–6 were synthesized and evalu-
ated for Fhit inhibition that link two 5'-O-phospho-
rothioadenosyl or AMP groups with five reagents
ranging in size from ethylene glycol to meso-erythritol.
Sodium salts of each compound were titrated into assays
of purified Fhit [16] with 1.8 µM fluorescent substrate,
Appp-S-(4-4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-
s-indacine-3-yl)methylaminoacetyl (ApppBODIPY)
[10], and competitive Ki values were obtained by calcu-
lating the inhibitor concentration-dependence in reduc-
tion of kcat/Km(apparent) for substrate hydrolysis [10].
As shown in Table 1, inhibitors 2b and 3b with two-car-
bon diol linkers were either only as inhibitory as the nat-
ural substrate 1 or substantially less so. Inhibitor 4b with
a four-carbon linker was as ineffective as 3b. Inhibitors
5a and 6a that substitute a central CH2-PO2-CH2 or
CH2-CH(OH)-CH2 for the PO2-O-PO2 of 1 were as inhib-
itory as 1 is a good substrate. The phosphorothioate ana-
logs, 5b and 6b, bound approximately 10 and 75 times
better to Fhit than 1. Thus, conservation of bond-lengths
between adenylate moieties of 1, 5 and 6 is conducive to
binding Fhit.
Because phosphorothioate analogs of 5 and 6 were bet-
ter inhibitors than the corresponding phosphates, phos-
phorodithioate analog 6c was prepared together with
five additional compounds as phosphates and phospho-
rothioates. Phosphorodithioate 6c was a less effective in-
hibitor (Ki = 8600 nM, not shown in Tables) than
corresponding phosphate 6a and phosphorothioate 6b
and, as demonstrated in Tables 1 and 2, the phospho-
rothioate congener of every compound made as a phos-
phate and a phosphorothioate had a lower Ki value. The
contribution of particular P-chiral phosphorothioate
stereoisomers to inhibition has not been examined.
When diadenosine 5',5"'-(P1, P2-methylene-P3-thio)-P1,
P3-triphosphate[17] was crystallized with wild-type and
mutant Fhit, the α -phosphorothioate group was found in
the mutant but not wild-type active site, suggesting that
α -phosphorothioate inhibitors may be slow substrates
Figure 1
Structures of Fhit substrate 1 and Fhit inhibitors 6b and 12b.BMC Chemical Biology 2001, 1:3 http://www.biomedcentral.com/1472-6769/1/3
[12]. Similarly, Frey and co-workers found that Fhit
slowly cleaves both Rp and Sp stereoisomers of γ -(m-ni-
trobenzyl)-adenosine 5'-O-(l-thiotriphosphate) with
modest and similar beneficial effects on Km as compared
to the corresponding phosphate [13].
Given the inhibitor activity of 6b, the contribution of the
oxygen in the position of the α -β  bridging oxygen of 1 was
examined. As can be seen in Table 2, comparison of 9b
with 10b and 11b and of 15b with 16b indicated that im-
ido or sulfur substitutions for oxygen reduce enzyme in-
hibition by an order of magnitude. Derivatives of 6b with
Table 1 :  Fhit inhibition by AppppA analogs varied in interadenylate linker and phosphorothiolation. 
 
X = O  X = S 
Comp.  R1  K i (nM) K i (nM)
a  b 
1   2600 -
2   - 2600
3   - 86000
4   - 86000
5   1500 220
6   4700 35
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one or two additional functionalities on the central car-
bon were characterized. Analysis of 9b indicated that
loss of the polar hydroxyl group reduces inhibitory activ-
ity and analysis of 7b and 8b indicated that nearly isos-
teric groups that are nonisoelectronic are not tolerated.
The magnitude of these effects was surprising and may
be related to altered conformations upon manganese co-
ordination. Earlier, Blackburn and co-workers made "su-
percharged" methane-trisphosphonic acid AppppA
analogs containing a central carbon from which three
adenylate or phosphate moieties are bonded [15]. In
work presented here, tripodal inhibitors 15a and 17a
showed, respectively, micromolar and submicromolar
efficacies while the phosphorothioate counterparts 15b
and 17b showed 100 nM efficacy.
Derivatives of pentaerythritol, tetrapodal compounds
12,13 and 14, were also evaluated for Fhit inhibition.
While compound 14b, containing two phospho-
rothioylated branches without adenosine, was barely a
submicromolar inhibitor, compounds 12b and 13b,
which contain respectively three and four CH2-phospho-
rothioadenosyl groups bonded to the central carbon
were 40 nM and 65 nM inhibitors. Thus, while the sim-
plest compound 6b was initially rendered less inhibitory
by modification because its central hydroxyl was impor-
tant for inhibition, addition of one or two CH2-phospho-
rothioadenosyl groups restored inhibition. We presume
that compounds 6b, 12b and 13b with 2, 3 or 4 identical
CH2-phosphorothioadenosyl groups can present a man-
ganese bound 6b-like complex to Fhit in a similar man-
ner. On the basis that Fhit binds diadenosine
polyphosphates with one AMP group buried and the oth-
er adenosine solvent-exposed in a specific conformation
[12], effective tri and tetrapodal inhibitors such as 12b,
13b and HC(ADP)3 [15] may exist in solution predomi-
nantly in a conformation that resembles Fhit-bound
AppppA.
On the basis of observations [12,13] discussed above, one
would expect AppppA with two phosphorothioadenosyl
substituents to be a slow substrate with a relatively low
Km. However, carbon in place of the β  phosphorus (for
example in 6b) would make the leaving group the alkox-
ide – OCH2-CH(OH)-CH2O-phosphorothioadenosyl
rather than α -thio ATP. Presumably, because normal
Fhit products are mononucleotides with low pKa values,
the enzyme does not have a group to protonate an alkox-
ide leaving group and thus substitution of carbon for the
β  phosphorus turns a substrate into an inhibitor.
Table 2 :  Fhit inhibition by AppppA analogs varied in phosphorothiolation and three modifications of glycerol. 
 
X = O  X = S 
Comp  R1  R2  R3  K i (nm) K i (nM)
a  b 
6 O OH H 4700 35
7 OC H 3 H - 76000
8 ON H 3 H - 3000
9 O H H - 230
10 NH H H - 3300
11 S H H - 5200
12 O- C H 2-O-P-(X,O)-OAdo -CH2-O-P-(X,O2) 1500 40
13 O- C H 2-O-P-(X,O)-OAdo -CH2-O-P-(X,O)-OAdo 3200 65
14 O- C H 2O-P-(X,O2)- C H 2-O-P-(X,O2) 900 700
15 O -O-P-(X,O)-OAdo H 1500 78
16 NH -O-P-(X,O)-OAdo H - 2700
17 O -O-P-(X,O2) H 420 110
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Conclusions 
Tumor suppression by Fhit is not destroyed by mutation
of the nucleophilic His96 to Asn, a mutation that specif-
ically reduces k cat [2,12]. Thus, evidence suggests that
the proapoptotic function of Fhit depends on formation
of an E-S complex. If the substrate-dependent signaling
model is correct, then compound 6b, as a nearly isosteric
AppppA analog with a low Ki, may promote Fhit signal-
ing in Fhit+ cells. Compound 12b, which one would ex-
pect to bind Fhit with bulky phosphorothioate and
phosphorothioadenosyl groups interfering with putative
effector binding, may consequently prove to be antago-
nistic to Fhit function. Ongoing in vitro studies aim to
evaluate the stereochemistry of phosphorothioyl binding
to Fhit while in vivo studies test the effects of these com-
pounds on programmed cell death. Phosphorothioate
analogs 6b and 12b that preserve the α -β  bridging oxy-
gen but substitute carbon for the β  phosphorus, achiev-
ing 65 to 75-fold binding advantages over AppppA, are
expected to be critical for cell biological characterization.
Materials and Methods 
Synthesis and Characterization 
The synthesis and physicochemical characteristics of
compounds 5, 6a and b, 12 through 15, and 17 have
been described [14]. Compounds 2–5, 8b, 9b were ob-
tained in the reaction of two equivalents of 5'-O-(2-thio-
no-1,3,2-oxathiaphospholane)-N6,N6,O2',O3'-
tetrabenzoyladenosine (18) with one equivalent of ethyl-
ene glycol (for 2b); O,O-dimethyl-D,L-tartrate (for 3b);
meso-erythritol (for 4b);  O-methyl bis(hydroxyme-
thyl)phosphinate (for 5); 2-amino-1,3-propanediol (for
8b); 1,3-propanediol (for 9b). To prepare compound 6c,
two equivalents of 5'-O-(2-thiono-1,3,2-dithiaphos-
pholane)-N6,N6,O2',O3'-tetrabenzoyladenosine (19)
were condensed with one equivalent of glycerol. Com-
pounds 7b, 10b, 11b, 16b were obtained in the reaction
of N6,N6,O2',O3'-tetrabenzoyladenosine with 2-thiono-
1,3,2-oxathiaphospholane derivatives of 2-methyl-1,3-
propanediol (for 7b); 1,3-diaminopropane (for 10 b);
1,3-propanedithiol (for 11b) and l,3-diamino-2-hydroxy-
propane (for 16b). Compounds 12 through 14 were ob-
tained in the reaction of tetra-oxathiaphosphothioylated
erythritol (20) with two equivalents of -N6,N6,O2',O3'-
tetrabenzoyladenosine (21) for 12; three equivalents of
21 for 13; four equivalents of 21 for 14. Compound 15
was obtained in the reaction of tri-oxathiaphospho-
thioylated glycerol (22) with three equivalents of com-
pound 21 [14].
Synthesis of 5'-O-(2-thiono-1, 3, 2-oxathiaphospholane)-
N6,N6,O2',O3'-tetrabenzoyladenosine (18) 
N6,N6,O2',O3'-tetrabenzoyladenosine (1 mmol) was re-
acted with 2-chloro-1,3,2-oxathiaphospholane (1.1
mmol) in pyridine solution (3 ml) in the presence of ele-
mental sulfur (5 mmol). After stirring for 12 h at room
temperature, the solvent was removed under reduced
pressure and the crude product was purified by silica gel
column chromatography using chloroform:hexane (8:2)
as an eluent to provide 18 in 72% yield [31P NMR 105.2
ppm (d), FAB-MS (M-1) m/z 820].
Synthesis of 5'-O-(2-thiono-1,3,2-dithiaphospholane)-N6,N6,O2',O3'-
tetrabenzoyladenosine (19) 
N6,N6,O2',O3'-tetrabenzoyladenosine (1 mmol) was re-
acted with 2-chloro-1,3,2-dithiaphospholane [18] in py-
ridine solution (3 ml) in the presence of elemental sulfur
(5 mmol). After stirring for 12 h at room temperature, the
solvent was removed under reduced pressure and the
crude product was purified by silica gel column chroma-
tography using chloroform:hexane (8:2) as an eluent to
give 19 in 68% yield [31P NMR 115.2 ppm, FAB-MS (M-
1) m/z 836].
Synthesis of tetra-oxathiaphosphothioylated erythritol (20) or tri-ox-
athiaphosphothioylated glycerol (21) 
2-chloro-1,3,2-oxathiaphospholane (8 mmol) was added
to a suspension of elemental sulfur (10 mmol) in pyridine
(10 ml). A solution of glycerol (1.5 mmol) or erythritol
(1.5 mmol) in pyridine (1 ml) was then introduced to the
reaction mixture and stirred for 12 h at room tempera-
ture. Crude products were purified by silica gel column
chromatography using chloroform:hexane (7:3) to give
22 in 77% yield [31P NMR 105.6 ppm (m), FAB-MS (M-
l) m/z 505] or 21 in 60% yield [31P NMR 105.1 ppm (m),
FAB-MS (M-1) m/z 687], respectively.
Condensation of oxathiaphospholane derivatives with polyols 
A mixture of 1,8-diazabicyclo(5,4,0) undec-7-ene with
the corresponding polyol (one equivalent of 1,8-diazabi-
cyclo(5,4,0) undec-7-ene per -OH function) in 1 ml ace-
tonitrile solution was added to the solution of one molar
equivalent of oxathiaphospholane derivative (18,19,20
or 21) dissolved in dry acetonitrile (5 ml). The reaction
mixtures were stirred at room temperature for 4 hours
and then solvent was removed under reduced pressure.
Purified compounds were obtained by Sephadex A-25
ion-exchange chromatography using a linear gradient of
ammonium bicarbonate buffer (pH 7.5) as eluent, and
their physicochemical characteristics are given in Table
3.
Enzyme inhibition assays 
Inhibitors, at approximately 4,2, 1, 0.5 and 0.25 times
Ki value, were added to assays of Fhit with ApppBODIPY
[10]. Ki values were obtained by calculating the inhibitor
concentration-dependence in reduction of kcat/Km (ap-
parent) as earlier described [10].BMC Chemical Biology 2001, 1:3 http://www.biomedcentral.com/1472-6769/1/3
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